Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Tianjin Medical University Second Hospital · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
kidneypaclitaxelpd
renal pelvic carcinoma, tislelizumab, pd-1 inhibitor, kidney-sparing, nab-paclitaxel, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 901417
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.